Skip to content

Clinical trials

Arthritis, Rheumatoid trials with unknown status

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Arthritis, Rheumatoid Status: Unknown status Clear all

436 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20001
20011
20031
20045
20053
20066
20078
20084
200910
20109
201117
201217
201316
201421
201522
201625
201721
201841
201937
202039
202136
202241
202331
202421

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Unknown status436

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
Assiut University19
University Hospital, Montpellier10
Guang'anmen Hospital of China Academy of Chinese Medical Sciences9
Peking Union Medical College Hospital7
Hanyang University6
National Taiwan University Hospital6
Assistance Publique - Hôpitaux de Paris5
Chengdu PLA General Hospital5
Fondazione Policlinico Universitario Agostino Gemelli IRCCS5
Jiangsu Simcere Pharmaceutical Co., Ltd.5

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Arthritis, Rheumatoid436
Arthritis, Psoriatic27
Spondylitis, Ankylosing21
Arthritis20
Lupus Erythematosus, Systemic18
Osteoarthritis18
Spondylarthritis13
Lung Diseases, Interstitial12
Crohn Disease9
Periodontitis8

Trials

Showing 51 to 75 of 436. Each trial links to its page on Pharma Observatory.

336 more trials match. See them on Pharma Observatory

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

No changes to these trials in the last 7 days.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.